| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.12 | 0.009 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.099 | 0.009 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.01 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |